Information Provided By: 
Fly News Breaks for February 16, 2017
ALKS
Feb 16, 2017 | 09:05 EDT
Cowen analyst Chris Shibutani noted Alkermes reported strong Q4 results and guidance, which he said supports his investment thesis. His thesis remains underpinned by strong growth for Vivitrol, which he believes is a durable growth franchise and underappreciated by Wall Street. He also remains optimistic on the company's pipeline. Shibutani reiterated his Outperform rating and $65 price target on Alkermes shares.
News For ALKS From the Last 2 Days
